Clinical Trials Browser

Brentuximab Vedotin × Lymphoid × 1 year × Clear all

NCT01868451 2026-06-04

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Phase NA Completed

Hodgkin Disease

NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Phase 3 Recruiting

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

NCT07624838 2026-06-03

Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain

Lymphoma, T-Cell, Peripheral

NCT04685616 2026-06-02

RADAR

Phase 3 Recruiting

Hodgkin Disease

NCT03907488 2026-06-01

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Phase 3 Active not recruiting

994 enrolled 11 charts 1 FDA

Hodgkin Disease

NCT01476410 2026-05-22

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Phase 2 Completed

49 enrolled 25 charts

Hodgkin Disease

NCT07013565 2026-05-20

ACCELERATE

Phase 2 Recruiting

Lymphoma, Large-Cell, Anaplastic

NCT01703949 2026-05-12

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

Phase 2 Active not recruiting

28 enrolled 11 charts

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT01920932 2026-05-06

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Phase 2 Active not recruiting

77 enrolled 20 charts

Hodgkin Disease, Neoplasms

NCT03057795 2026-05-01

Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

Phase 2 Active not recruiting

62 enrolled 8 charts

Hodgkin Disease

NCT03755804 2026-04-23

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Phase 2 Active not recruiting

Hodgkin Disease, Neoplasms

NCT06377566 2026-04-23

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Phase 2 Recruiting

Hodgkin Disease

NCT04404283 2026-04-20

ECHELON-3

Phase 3 Active not recruiting

239 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT05922904 2026-04-15

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Phase 2 Active not recruiting

Hodgkin Disease

NCT05481437 2026-04-13

A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma

Hodgkin Disease

NCT05414500 2026-04-09

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

Phase 1 Recruiting

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT03587844 2026-04-03

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Phase 2 Recruiting

Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis

NCT01712490 2026-02-27

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Phase 3 Completed

1,334 enrolled 23 charts

Hodgkin Disease, Lymphoma

NCT06831370 2026-02-23

A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India

Phase 4 Recruiting

Hodgkin Disease, Lymphoma

NCT02684292 2026-02-18

MK-3475-204

Phase 3 Completed

304 enrolled 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease

NCT04569032 2026-02-18

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Phase 2 Completed

82 enrolled 13 charts

Lymphoma, T-Cell, Peripheral

NCT05180097 2026-02-02

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Phase 2 Recruiting

Hodgkin Disease

NCT01352520 2026-01-20

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Phase 2 Active not recruiting

DermatologicLymphoid

Hematologic Diseases, Lymphoma, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT05357794 2026-01-12

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

Phase 2 Recruiting

Mycosis Fungoides

NCT07258680 2025-12-02

BrEto-TCL

Phase 3 Enrolling by invitation

Lymphoma, T-Cell, Peripheral

NCT02588651 2025-11-21

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Phase 2 Completed

23 enrolled 15 charts

LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT02227199 2025-11-18

BV-ICE

Phase 1/2 Completed

45 enrolled 14 charts

Hodgkin Disease

NCT03113500 2025-11-14

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Phase 2 Active not recruiting

48 enrolled 8 charts

LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Enteropathy-Associated T-Cell Lymphoma

NCT02979522 2025-11-10

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Phase 1/2 Active not recruiting

59 enrolled 63 charts

Hodgkin Disease

NCT07002216 2025-11-03

BrECADD

Phase 2 Recruiting

Hodgkin Disease

NCT01508312 2025-10-21

Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Completed

66 enrolled 14 charts

Hodgkin Disease

NCT01909934 2025-09-19

Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Phase 4 Completed

50 enrolled 22 charts

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT05442554 2025-09-18

A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

Phase 4 Completed

10 enrolled 25 charts

Lymphoma, T-Cell

NCT07178457 2025-09-17

BeCALM

Phase 3 Not yet recruiting

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT03646123 2025-08-28

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Phase 2 Terminated

255 enrolled 29 charts

Hodgkin Disease

NCT02734771 2025-08-12

BV mini CHP

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT03719105 2025-08-08

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

Phase EARLY_PHASE1 Recruiting

LymphoidOther hematologic neoplasm

Lymphoma, T-Cell, Peripheral, Leukemia, Large Granular Lymphocytic

NCT03496779 2025-07-30

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

Phase 2 Completed

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT03409432 2025-07-25

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Phase 2 Completed

DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT05673785 2025-07-14

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

Phase 2 Active not recruiting

Lymphoma